CCA
VRCA icon

Catalyst Capital Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

Catalyst Capital Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-29
Closed -$5K – 497
2018
Q3 		$5K Hold
29
– – ﹤0.01% 410
2018
Q2 		$6K Buy
+29
New +$5.68K ﹤0.01% 425

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CI
Conning Inc Hartford, Connecticut $3.34B AUM 25.19% 1-Year Est. Return

Catalyst Capital Advisors's VRCA Position: Q4 2018 in Review

Catalyst Capital Advisors sold out of Verrica Pharmaceuticals (VRCA) in Q4 2018, closing a stake of 29 shares — an estimated $5K sold.

Catalyst Capital Advisors first reported a position in VRCA in Q2 2018 and held it in 2 quarters. The position peaked at $6K in Q2 2018. 40 funds tracked by Wall St. Rank hold VRCA as of Q4 2018.

  • Catalyst Capital Advisors reported no remaining Verrica Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 29 Verrica Pharmaceuticals shares in Q4 2018, an estimated $5K.
  • Catalyst Capital Advisors first reported a position in Verrica Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Catalyst Capital Advisors's Verrica Pharmaceuticals position peaked at $6K in Q2 2018.
  • 40 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2018.

Based on Catalyst Capital Advisors's 13F filing for Q4 2018, filed 7 Feb 2019.